Physician profile
Ceida P Chan
NPI 1023028057
$2,792.99
in general payments reported to CMS, 2019-2025
17 companies · $798 in 2025
The $798 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $81.73 · 2021: $102 · 2022: $486 · 2023: $425 · 2024: $754 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,977.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $476.52 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $474.51 | 2022-2025 | Photrexa Viscous and Photrexa, Idosetr, Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $381.72 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $356.16 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $244.92 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $206.33 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $127.00 | 2022 | |
| Shire North American Group INC | $121.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $120.29 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $75.21 | 2021-2022 | |
| Dompe US, INC. | $72.07 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $33.38 | 2025 | Rocklatan |
| Beaver-Visitec International, INC. | $25.28 | 2023 | |
| Kala Pharmaceuticals, INC. | $23.91 | 2021 | |
| Sight Sciences, INC. | $23.04 | 2023 | Tearcare System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $17.15 | 2022 | |
| Allergan, INC. | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ceida Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.